Development of Potent and Selective NUAK1 Inhibitors for Neurodegenerative Diseases

A team of researchers from the University of Cambridge has made significant progress in developing potent and selective inhibitors of the NUAK1 protein kinase, a key player in various cellular functions including cell proliferation, migration, and adhesion. This research, funded by Alzheimer's Research UK (ARUK) and the ALBORADA Trust, has led to the discovery of several inhibitors with improved efficacy and pharmacokinetic properties. The most promising compound, ARUK2010489, exhibits high brain penetration and no CDK2 activity, making it an attractive candidate for CNS pharmacological studies.

Key Takeaways:

• The research focuses on NUAK1, a protein kinase implicated in tau phosphorylation and stabilization, a process linked to neurodegenerative diseases.
• The team developed a series of potent and selective NUAK1 inhibitors, including ARUK2010694 and ARUK2010489, with improved mouse plasma half-lives and brain penetration.
• The most promising compound, ARUK2010489, shows a significantly improved unbound brain/plasma ratio (Kp,u,ub) of 2.29 and displays no CDK2 activity.
• The discovery of these inhibitors enables the study of NUAK1's role in neurodegenerative diseases and the development of therapeutic interventions.
• The research was funded by Alzheimer's Research UK (ARUK) and the ALBORADA Trust through the ALBORADA Drug Discovery Institute.

Statistics:

• The research team developed several potent and selective NUAK1 inhibitors, with one compound (ARUK2010489) displaying a Kp,u,ub of 2.29.
• The most promising compound, ARUK2010489, exhibits no CDK2 activity and has a significantly improved mouse plasma half-life.
• The study highlights the potential of NUAK1 as a target for neurodegenerative disease treatment, with one compound displaying high brain penetration.

Sources:

• Development of Purine and Pyrrolopyrimidine Scaffolds As Potent, Selective, and Brain Penetrant Nuak1 Inhibitors. Acs Medicinal Chemistry Letters, 2025.
• Acs Medicinal Chemistry Letters, Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA (www.acs.org; pubs.acs.org/journal/amclct).